{"id":675855,"date":"2023-11-08T18:38:01","date_gmt":"2023-11-08T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675855"},"modified":"2023-11-08T18:38:01","modified_gmt":"2023-11-08T18:38:01","slug":"sleep-apnoea-syndrome-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-bayer-apnimed-respirerx-merck-takeda-therapix","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sleep-apnoea-syndrome-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-bayer-apnimed-respirerx-merck-takeda-therapix_675855.html","title":{"rendered":"Sleep Apnoea Syndrome Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Bayer, Apnimed, RespireRx, Merck, Takeda, Therapix"},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Sleep Apnoea Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\">&ldquo;<strong>Sleep Apnoea Syndrome Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Sleep Apnoea Syndrome Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Sleep Apnoea Syndrome Pipeline report embraces in-depth commercial, regulatory, and Sleep Apnoea Syndrome clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Sleep Apnoea Syndrome drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sleep-apnoea-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Sleep Apnoea Syndrome Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Sleep Apnoea Syndrome treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Sleep Apnoea Syndrome therapies segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Sleep Apnoea Syndrome companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Sleep Apnoea Syndrome drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sleep Apnoea Syndrome therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/92e6d1561fb907c83187d3f48bc41c11.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sleep Apnoea Syndrome Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. <strong>10+ key companies developing therapies for Sleep Apnoea Syndrome<\/strong>. Currently, <strong>Apnimed<\/strong> is leading the therapeutics market with its Sleep Apnoea Syndrome drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sleep Apnoea Syndrome Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Apnimed<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cortex Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RespireRx Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Taisho Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck Sharp &amp; Dohme Corp.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Janssen Research &amp; Development<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Minerva Neurosciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Therapix Biosciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Idorsia Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Sleep Apnoea Syndrome Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AD128: Apnimed<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BAY2586116: Bayer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Sleep Apnoea Syndrome Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Sleep Apnoea Syndrome Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sleep Apnoea Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Sleep Apnoea Syndrome Treatment Outlook will Evolve with the Ongoing Clinical &amp; Commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Sleep Apnoea Syndrome Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Sleep Apnoea Syndrome &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Sleep Apnoea Syndrome Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Sleep Apnoea Syndrome Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Sleep Apnoea Syndrome Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Sleep Apnoea Syndrome Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Sleep Apnoea Syndrome Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Sleep Apnoea Syndrome Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Sleep Apnoea Syndrome Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Sleep Apnoea Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Sleep Apnoea Syndrome Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Sleep Apnoea Syndrome Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/sleep-apnoea-syndrome-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/microscopic-polyangiitis-mpa-market\">Microscopic Polyangiitis (MPA) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Microscopic Polyangiitis (MPA) Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Microscopic Polyangiitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Microscopic Polyangiitis market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sleep-apnoea-syndrome-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-bayer-apnimed-respirerx-merck-takeda-therapix\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/market-research\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/market-research<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/market-research\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sleep-apnoea-syndrome-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-bayer-apnimed-respirerx-merck-takeda-therapix\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Sleep Apnoea Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sleep-apnoea-syndrome-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-bayer-apnimed-respirerx-merck-takeda-therapix_675855.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-675855","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675855"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675855\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}